Q2 EPS Estimates for Urogen Pharma Boosted by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for Urogen Pharma in a research report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.61) per share for the quarter, up from their prior forecast of ($0.64). HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.26) EPS and Q2 2027 earnings at ($0.02) EPS.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million.

A number of other equities research analysts also recently weighed in on the company. Oppenheimer lifted their target price on Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. D. Boral Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research report on Monday. They set a “buy” rating and a $43.00 target price on the stock. Finally, Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.67.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $29.80 on Wednesday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $32.37. The business’s 50-day moving average is $21.13 and its 200-day moving average is $21.83. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -10.84 and a beta of 1.58.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of URGN. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. State of Wyoming bought a new stake in Urogen Pharma in the 3rd quarter worth about $66,000. Russell Investments Group Ltd. increased its stake in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Urogen Pharma in the 3rd quarter valued at about $76,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.